Based on the Merck & Company Inc stock forecast from 0 analysts, the average analyst target price for Merck & Company Inc is not available over the next 12 months. Merck & Company Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Merck & Company Inc is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Merck & Company Inc’s stock price was USD 99.50. Merck & Company Inc’s stock price has changed by -1.87% over the past week, -3.86% over the past month and -15.82% over the last year.
No recent analyst target price found for Merck & Company Inc
No recent average analyst rating found for Merck & Company Inc
Company Overview Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. Read Less
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virolo...Read More
Frequently Asked Questions About Merck & Company Inc (0QAH:LSE) Stock
Stock Target Advisor's fundamental analysis for Merck & Company Inc's stock is Slightly Bullish .
0QAH:LSE stock's dividend yield is 3.27%.
Our analysis grades 0QAH:LSE stock's dividend yield at F. This means that 0QAH:LSE stock's dividend yield is above 50% of the stocks in the Drug Manufacturers - General sector in the LSE exchange.
Based on this 0QAH:LSE may be a average dividend stock for its sector.
Unfortunately we do not have enough data on 0QAH:LSE's stock to indicate what its average analyst target is.
0QAH:LSE stock's Price/Earning ratio is 0.19.
Our analysis grades 0QAH:LSE stock's Price / Earning ratio at A+. This means that 0QAH:LSE stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - General sector in the LSE exchange.
Based on this 0QAH:LSE may be undervalued for its sector.
The last closing price of 0QAH:LSE's stock was USD 99.50.
Unfortunately we do not currently have any market capitalization data for 0QAH:LSE's stock.
Unfortunately we do not have enough analyst data on 0QAH:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Merck & Company Inc's stock.
As per our most recent records Merck & Company Inc has 70,000 Employees.
Merck & Company Inc's registered address is 126 East Lincoln Avenue, Rahway, NJ, United States, 07065.
You can get more information about it from Merck & Company Inc's website at https://www.merck.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Merck & Company Inc (0QAH:LSE) Stock
Stock Target Advisor's fundamental analysis for Merck & Company Inc's stock is Slightly Bullish .
0QAH:LSE stock's dividend yield is 3.27%.
Our analysis grades 0QAH:LSE stock's dividend yield at F. This means that 0QAH:LSE stock's dividend yield is above 50% of the stocks in the Drug Manufacturers - General sector in the LSE exchange.
Based on this 0QAH:LSE may be a average dividend stock for its sector.
Unfortunately we do not have enough data on 0QAH:LSE's stock to indicate what its average analyst target is.
0QAH:LSE stock's Price/Earning ratio is 0.19.
Our analysis grades 0QAH:LSE stock's Price / Earning ratio at A+. This means that 0QAH:LSE stock's Price/Earning ratio is above 0% of the stocks in the Drug Manufacturers - General sector in the LSE exchange.
Based on this 0QAH:LSE may be undervalued for its sector.
The last closing price of 0QAH:LSE's stock was USD 99.50.
Unfortunately we do not currently have any market capitalization data for 0QAH:LSE's stock.
Unfortunately we do not have enough analyst data on 0QAH:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Merck & Company Inc's stock.
As per our most recent records Merck & Company Inc has 70,000 Employees.
Merck & Company Inc's registered address is 126 East Lincoln Avenue, Rahway, NJ, United States, 07065.
You can get more information about it from Merck & Company Inc's website at https://www.merck.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0QAH:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
